María José Ariza1, Pedro Luis Martínez-Hernández2, Daiana Ibarretxe3, Claudio Rabacchi4, José Rioja5, Cristina Grande-Aragón6, Nuria Plana3, Patrizia Tarugi4, Gunilla Olivecrona7, Sebastiano Calandra8, Pedro Valdivielso9. 1. Department of Medicine and Dermatology, Lipids and Atherosclerosis Laboratory, CIMES, University of Málaga, Málaga, Spain. Electronic address: mariza@uma.es. 2. Department of Internal Medicine, La Paz University Hospital, Madrid, Spain. 3. Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain. 4. Department of Life Sciences, University of Modena & Reggio Emilia, Modena, Italy. 5. Department of Medicine and Dermatology, Lipids and Atherosclerosis Laboratory, CIMES, University of Málaga, Málaga, Spain. 6. Department of Biochemistry, La Paz University Hospital, Madrid, Spain. 7. Department of Medical Biosciences, Physiological Chemistry, Umeå University, Umeå, Sweden. 8. Department of Biomedical, Metabolic and Neural Sciences, University of Modena & Reggio Emilia Modena, Italy. 9. Department of Medicine and Dermatology, Lipids and Atherosclerosis Laboratory, CIMES, University of Málaga, Málaga, Spain; Internal Medicine Unit, Virgen de la Victoria University Hospital, Málaga, Spain.
Abstract
BACKGROUND: Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) has been demonstrated to be essential for the in vivo function of lipoprotein lipase (LPL), the major triglyceride (TG)-hydrolyzing enzyme involved in the intravascular lipolysis of TG-rich lipoproteins. Recently, loss-of-function mutations of GPIHBP1 have been reported as the cause of type I hyperlipoproteinemia in several patients. METHODS: Two unrelated patients were referred to our Lipid Units because of a severe hypertriglyceridemia and recurrent pancreatitis. We measured LPL activity in postheparin plasma and serum ApoCII and sequenced LPL, APOC2, and GPIHBP1. RESULTS: The 2 patients exhibited very low LPL activity not associated with mutations in LPL gene or with ApoCII deficiency. The sequence of GPIHBP1 revealed 2 novel point mutations. One patient (proband 1) was found to be homozygous for a C>A transversion in exon 3 resulting in the conversion of threonine to lysine at position 80 (p.Thr80Lys). The other patient (proband 2) was found to be homozygous for a G>T transversion in the third base of the ATG translation initiation codon in exon 1, resulting in the conversion of methionine to isoleucine (p.Met1Ile). CONCLUSION: In conclusion, we have identified 2 novel GPIHBP1 missense mutations in 2 unrelated patients as the cause of their severe hypertriglyceridemia.
BACKGROUND:Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) has been demonstrated to be essential for the in vivo function of lipoprotein lipase (LPL), the major triglyceride (TG)-hydrolyzing enzyme involved in the intravascular lipolysis of TG-rich lipoproteins. Recently, loss-of-function mutations of GPIHBP1 have been reported as the cause of type I hyperlipoproteinemia in several patients. METHODS: Two unrelated patients were referred to our Lipid Units because of a severe hypertriglyceridemia and recurrent pancreatitis. We measured LPL activity in postheparin plasma and serum ApoCII and sequenced LPL, APOC2, and GPIHBP1. RESULTS: The 2 patients exhibited very low LPL activity not associated with mutations in LPL gene or with ApoCII deficiency. The sequence of GPIHBP1 revealed 2 novel point mutations. One patient (proband 1) was found to be homozygous for a C>A transversion in exon 3 resulting in the conversion of threonine to lysine at position 80 (p.Thr80Lys). The other patient (proband 2) was found to be homozygous for a G>T transversion in the third base of the ATG translation initiation codon in exon 1, resulting in the conversion of methionine to isoleucine (p.Met1Ile). CONCLUSION: In conclusion, we have identified 2 novel GPIHBP1 missense mutations in 2 unrelated patients as the cause of their severe hypertriglyceridemia.
Authors: Katrine Z Leth-Espensen; Kristian K Kristensen; Anni Kumari; Anne-Marie L Winther; Stephen G Young; Thomas J D Jørgensen; Michael Ploug Journal: Proc Natl Acad Sci U S A Date: 2021-03-23 Impact factor: 11.205
Authors: Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux Journal: J Clin Lipidol Date: 2017-06-13 Impact factor: 4.766
Authors: Christopher M Allan; Mikael Larsson; Xuchen Hu; Cuiwen He; Rachel S Jung; Alaleh Mapar; Constance Voss; Kazuya Miyashita; Tetsuo Machida; Masami Murakami; Katsuyuki Nakajima; André Bensadoun; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux Journal: J Lipid Res Date: 2016-08-05 Impact factor: 5.922
Authors: Kristian K Kristensen; Katrine Zinck Leth-Espensen; Haydyn D T Mertens; Gabriel Birrane; Muthuraman Meiyappan; Gunilla Olivecrona; Thomas J D Jørgensen; Stephen G Young; Michael Ploug Journal: Proc Natl Acad Sci U S A Date: 2020-02-07 Impact factor: 11.205
Authors: Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux Journal: J Lipid Res Date: 2020-09-18 Impact factor: 5.922
Authors: Christopher M Allan; Mikael Larsson; Rachel S Jung; Michael Ploug; André Bensadoun; Anne P Beigneux; Loren G Fong; Stephen G Young Journal: J Lipid Res Date: 2016-11-03 Impact factor: 5.922
Authors: Stephen G Young; Loren G Fong; Anne P Beigneux; Christopher M Allan; Cuiwen He; Haibo Jiang; Katsuyuki Nakajima; Muthuraman Meiyappan; Gabriel Birrane; Michael Ploug Journal: Cell Metab Date: 2019-07-02 Impact factor: 27.287
Authors: Loren G Fong; Stephen G Young; Anne P Beigneux; André Bensadoun; Monika Oberer; Haibo Jiang; Michael Ploug Journal: Trends Endocrinol Metab Date: 2016-05-14 Impact factor: 12.015
Authors: Simon Mysling; Kristian Kølby Kristensen; Mikael Larsson; Oleg Kovrov; André Bensadouen; Thomas Jd Jørgensen; Gunilla Olivecrona; Stephen G Young; Michael Ploug Journal: Elife Date: 2016-12-08 Impact factor: 8.140